@article{033215d6db0b4d4d8472e82d83b8840f,
title = "NMO-IgG detected in CSF in seronegative neuromyelitis optica",
author = "Klawiter, \{E. C.\} and E. Alvarez and J. Xu and Paciorkowski, \{A. R.\} and L. Zhu and Parks, \{B. J.\} and Cross, \{A. H.\} and Naismith, \{R. T.\}",
note = "Funding Information: Disclosure: Drs. Klawiter, Alvarez, Xu, Paciorkowski, and Zhu have no disclosures to report. Dr. Parks is a participant in clinical trials for BioMS and Teva Neurosciences. She has received consulting fees or speaking honoraria from Biogen Idec, Bayer Healthcare, Teva Neurosciences, and Pfizer/Serono. Dr. Cross has received research funding, clinical trial funding, honoraria, or consulting fees from the NIH, National MS Society USA, Consortium of Multiple Sclerosis Centers, Genentech, Inc., Berlex (now Bayer Healthcare), Biogen-Idec, Teva Neuroscience, Acorda Therapeutics, Serono, Pfizer, and BioMS. Dr. Naismith is a participant in clinical trials for Fampridine SR by Acorda Therapeutics. He has received consulting fees and speaking honoraria from Bayer Healthcare, Biogen Idec, and Teva Neurosciences. Research funding is through the NIH and National MS Society. Funding Information: Supported by grant UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research. NIH funding included UL1RR024992 (E.C.K.), K23NS052430-01A1 (R.T.N.), K12RR02324902 (R.T.N.), K24 RR017100 (A.H.C.), CA1012 (A.H.C.); American Academy of Neurology Foundation Clinical Research Training Fellowship (E.C.K.); and National MS Society FG1782A1 (J.X.). Dr. Cross was supported in part by the Manny and Rosalyn Rosenthal–Dr. John L. Trotter Chair in Neuroimmunology. ",
year = "2009",
month = mar,
day = "24",
doi = "10.1212/01.wnl.0000345066.57745.50",
language = "English",
volume = "72",
pages = "1101--1103",
journal = "Neurology",
issn = "0028-3878",
number = "12",
}